Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: CPAMarty who wrote (95)	3/3/1999 5:10:00 PM
From: BRAVEHEART	Respond to of 423

NTII UPDATE: Positive Memantine Trial Results in Dementia & Alzheimer's Published In International Journal of Geriatric Psychiatry Phase III Trial Sponsored by Merz + Co. GmbH & Co. of Frankfurt, Germany, Corporate Collaborator of NTI(R) "RICHMOND, Calif., March 3 /PRNewswire/ -- Neurobiological Technologies, Inc. (OTC Bulletin Board: NTII - news) today announced positive results in a Phase III human clinical trial of Memantine in Europe sponsored by its corporate collaborator Merz + Co. GmbH & Co. of Frankfurt, Germany (Merz). In this trial, severely demented subjects treated with Memantine had statistically significant improvement compared to placebo in internationally accepted measures of functional independence, including bathing, dressing and self-care. The data are presented in the current issue of the peer-review International Journal of Geriatric Psychiatry, a publication of John Wiley & Sons." ''We are pleased by the publication of these Phase III Alzheimer's results,'' said Paul E. Freiman, president and chief executive officer of NTI®, ''indicating Memantine's promise in treating dementia. Merz and NTI® are collaborating to further the clinical development of Memantine, an oral drug with a history of safe clinical use in Germany. In addition to Merz's Alzheimer's program, this clinical development effort includes The company's Phase IIB trial of Memantine for painful diabetic neuropathy, as well as a Phase II trial of Memantine for the treatment of AIDS dementia conducted by the AIDS Clinical Trials Group of the NIH.'' biz.yahoo.com In my opinion things should begin to fall into place in the near future. PS: Hi Marty, I will check out my charts to give you my opinion on recent price/volume relationships. BEST WISHES Jeffrey

To: CPAMarty who wrote (95)	3/10/1999 8:54:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 423

Hi Marty, IMCL is clearly in a solid uptrend. Accumulation certainly. It tops out on each rise...The key is the tops & bottoms are trending up... I remember when Phizer came out with Viagra...ICOS rode the coat tails with it's product. IMCL announced it's potential is greater than GNE's... "Herceptin targets the human epidermal growth factor-2 (HER-2) gene, while C-225 targets HER-1 or EGF, which Waksal says is involved in a wide range of cancers." ''The market for our product is much larger,'' he said. ''Fully one-third of all human solid tumors express the EGF receptor.'' biz.yahoo.com The two announcements in conjunction with one another should do something for the stock. biz.yahoo.com ICOS took off last spring ( when I first targeted it ) on it's similarly structured story. Of course Pfizer received much more media attention of which ICOS benefited. I would still favor a favorable speculative trend. quote.yahoo.com BEST WISHES JEFFREY